 | Up a level |
van der Maas, Niek G; Versluis, Jurjen; Nasserinejad, Kazem; van Rosmalen, Joost; Pabst, Thomas; Maertens, Johan; Breems, Dimitri; Manz, Markus; Cloos, Jacqueline; Ossenkoppele, Gert J; Floisand, Yngvar; Gradowska, Patrycja; Löwenberg, Bob; Huls, Gerwin; Postmus, Douwe; Pignatti, Francesco; Cornelissen, Jan J (2024). Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial. Blood cancer journal, 14(56) Nature Publishing Group 10.1038/s41408-024-01037-3
Hilberink, Jacobien R; van Zeventer, Isabelle A; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2023). Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood cancer journal, 13(1), p. 93. Springer Nature 10.1038/s41408-023-00850-6
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Huls, Gerwin; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; van Zeventer, Isabelle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2020). Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood advances, 4(18), pp. 4267-4277. American Society of Hematology 10.1182/bloodadvances.2020002846
Ossenkoppele, Gert J; Stussi, Georg; Maertens, Johan; van Montfort, Kees; Biemond, Bart J; Breems, Dimitri; Ferrant, August; Graux, Carlos; de Greef, Georgine E; Halkes, C J M; Hoogendoorn, Mels; Hollestein, Rene M; Jongen-Lavrencic, Mojca; Levin, Mark D; van de Loosdrecht, Arjan A; van Marwijk Kooij, Marinus; van Norden, Yvette; Pabst, Thomas; Schouten, Harry C; Vellenga, Edo; ... (2012). Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood, 120(24), pp. 4706-11. Washington, D.C.: American Society of Hematology 10.1182/blood-2012-04-420596
Cornelissen, Jan J; Breems, Dimitri; van Putten, Wim L J; Gratwohl, Alois A; Passweg, Jakob R; Pabst, Thomas; Maertens, Johan; Beverloo, H Berna; van Marwijk Kooy, Marinus; Wijermans, Pierre W; Biemond, Bart J; Vellenga, Edo; Verdonck, Leo F; Ossenkoppele, Gert J; Löwenberg, Bob (2012). Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Journal of clinical oncology, 30(17), pp. 2140-6. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.39.6499
Löwenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C; Verdonck, Leo F; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, Ron; Verhoef, Gregor; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert J; ... (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), pp. 2586-91. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-10-246470
